Coverage
-
February 22, 2022
A New Jersey federal judge adopted a special master's report Tuesday approving two settlements totaling over $23 million to resolve claims that the former Valeant Pharmaceuticals used a "secret network of captive pharmacies" to stifle generic competition, driving up prices for third-party payors.
2 other articles on this case.
View all »